Page last updated: 2024-09-04

docetaxel anhydrous and pasireotide

docetaxel anhydrous has been researched along with pasireotide in 1 studies

Compound Research Comparison

Studies (docetaxel anhydrous)	Trials (docetaxel anhydrous)	Recent Studies (post-2010) (docetaxel anhydrous)	Studies (pasireotide)	Trials (pasireotide)	Recent Studies (post-2010) (pasireotide)
12,110	3,216	6,920	425	86	341

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Boerner, J; Dobson, K; Fontana, J; Heath, E; Heilbrun, L; Li, J; Smith, D; Stark, K; Thakur, MK; Vaishampayan, U	1

Trials

1 trial(s) available for docetaxel anhydrous and pasireotide

Article	Year
Phase I Trial of the Combination of Docetaxel, Prednisone, and Pasireotide in Metastatic Castrate-Resistant Prostate Cancer. Clinical genitourinary cancer, 2018, Volume: 16, Issue:3 Topics: Administration, Intravenous; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Prednisone; Prostatic Neoplasms, Castration-Resistant; Somatostatin; Treatment Outcome	2018

Article

Year

Phase I Trial of the Combination of Docetaxel, Prednisone, and Pasireotide in Metastatic Castrate-Resistant Prostate Cancer.

Clinical genitourinary cancer, 2018, Volume: 16, Issue:3

Topics: Administration, Intravenous; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Prednisone; Prostatic Neoplasms, Castration-Resistant; Somatostatin; Treatment Outcome

2018